StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1294.TWO$78.00+0.00%
Fair $78.00+0.0%

1294.TWO

Hantech Bio-Technology Co., Ltd.

Consumer Defensive / Packaged FoodsTaipei Exchange

$78.00

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $78.00Fund rank 27/100 · Data gapFallback financials|
SA 52/C
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $125.4M · quality 46.7/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 18/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

52/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 1294.TWOLocal privado en este navegador · Hantech Bio-Technology Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.4B

P/E

17.2x

↑

EV/EBITDA

10.3x

↑

ROE

16.8%

↑

Gross Margin

37.1%

↑

Debt/Equity

0.11

↓
52-Week Range$78
$64$95

TradingView lightweight chart

1294.TWO price, volumen y niveles de valoración

Último $78.00Periodo +204.9%
Fair value: $78.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+37.0%

FCF CAGR

—

FCF margin

18.5%

FCF / Net income

1.03x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $778.5M · net income $139.1M · FCF $143.9M

2022-FY → 2025-FY

Gross margin

37.1%-4.8% pts

Operating margin

22.3%+3.3% pts

Net margin

17.9%+2.2% pts

FCF margin

18.5%+25.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$778.5M$778.5M$748.4M$625.1M$302.5M
Net Income$139.1M$139.1M$155.7M$148.1M$47.5M
EBITDA$214.2M$214.2M$232.1M$207.6M$78.5M
EPS——5.335.231.82
Gross Margin37.1%37.1%40.9%44.9%41.9%
Operating Margin22.3%22.3%26.4%29.6%19.0%
Net Margin17.9%17.9%20.8%23.7%15.7%
Balance Sheet
Debt/Equity0.110.110.130.770.42
Current Ratio2.712.71———
Cash Flow
Free Cash Flow$143.9M$143.9M$125.4M$-105.3M$-20.4M
Returns
ROE16.8%16.8%19.0%37.2%17.8%
Valuation
P/E17.1817.1816.4615.2916.00
EV/EBITDA10.2810.288.8711.5810.15
P/B2.852.852.855.692.84
Growth & Yield
Revenue Growth4.0%4.0%19.7%106.6%—
EPS Growth——1.9%188.0%—
Dividend Yield3.6%3.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +9.4%

Total return

+9.4%

Start / end P/E

n/dx → n/dx

EPS bridge

5.33 → n/d

Residual

+5.7%

EPS growthn/d
Multiple reratingn/d
Dividend+3.6%
Residual / FX / buybacks / cross-term+5.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.